$ICCC News

ImmuCell Q1 Earnings Rise Y/Y as Sales Climb on Strong Demand

ImmuCell Corp (ICCC) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic Growth

ImmuCell Q1 Earnings Call Highlights

ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2026

ImmuCell Q1 EPS $0.21 Up From $0.16 YoY, Sales $10.357M Up From $8.067M YoY

Here’s Why ImmuCell Corporation (ICCC) is Emerging as an Intriguing Micro-Cap Opportunity

ImmuCell And Norbrook Laboratories Reach Settlement Agreement, Norbrook To Pay $2M Following Expiration Of 2019 Supply Deal

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2026

ImmuCell shares are trading higher after the company reported year-over-year increase in its Q1 preliminary sales results.

ImmuCell shares are trading higher after the company reported year-over-year increase in its Q1 preliminary sales results.

ImmuCell Announces a 28.4% Increase in Product Sales in Q1 of 2026, based on Preliminary, Unaudited Sales Results

ImmuCell Reports Q1 Preliminary Sales $10.4M Up From 28.4% YoY

ImmuCell Corp (ICCC) Q4 2025 Earnings Call Highlights: Navigating Growth Amidst Challenges

ImmuCell 2025 Net Loss Narrows Y/Y as Sales & Margins Improve

ImmuCell Q4 Earnings Call Highlights

ImmuCell Corporation (ICCC) Q4 2025 Earnings Call Transcript

ImmuCell Corporation Q4 2025 Earnings Call Summary

ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2025

ImmuCell Q4 EPS $(0.31) Down From $0.06 YoY, Sales $7.626M Down From $7.751M YoY

ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2025